Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Several other research analysts also recently commented on TEVA. Barclays lifted their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday, August 1st. Jefferies Financial Group upped their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday, June 27th. Argus upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. Finally, UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $18.89.
Check Out Our Latest Research Report on TEVA
Shares of NYSE TEVA traded down $0.06 during trading hours on Thursday, hitting $17.96. 3,088,471 shares of the stock were exchanged, compared to its average volume of 9,499,521. Teva Pharmaceutical Industries has a one year low of $8.06 and a one year high of $19.08. The company's 50 day moving average is $17.95 and its 200 day moving average is $16.59. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a market capitalization of $20.35 billion, a P/E ratio of -46.05, a P/E/G ratio of 1.20 and a beta of 0.88.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, research analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.
In other news, insider Eric A. Hughes sold 24,537 shares of the company's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.55% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. New Covenant Trust Company N.A. bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $30,000. UMB Bank n.a. boosted its stake in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $48,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $52,000. Institutional investors and hedge funds own 54.05% of the company's stock.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.